Mineralys Therapeutics, Inc. Common Stock
$ 29.96
3.56%
24 Feb - close price
- Market Cap 2,371,033,000 USD
- Current Price $ 29.96
- High / Low $ 30.05 / 27.76
- Stock P/E N/A
- Book Value 7.30
- EPS -2.92
- Next Earning Report 2026-03-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.42 %
- 52 Week High 47.65
- 52 Week Low 8.69
About
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.
Analyst Target Price
$51.29
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-11 | 2025-08-12 | 2025-05-12 | 2025-02-12 | 2024-11-11 | 2024-08-13 | 2024-05-09 | 2024-03-21 | 2023-11-07 | 2023-08-07 | 2023-05-15 | 2023-03-15 |
| Reported EPS | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.7 | -0.61 | -0.57 | -0.31 | -0.51 | -1.74 |
| Estimated EPS | -0.64 | -0.74 | -0.98 | -1.08 | -0.83 | -0.7 | -0.67 | -0.82 | -0.76 | -0.72 | -0.89 | -1.72 |
| Surprise | 0.12 | 0.08 | 0.19 | 0.1 | -0.3 | -0.13 | -0.03 | 0.21 | 0.19 | 0.41 | 0.38 | -0.02 |
| Surprise Percentage | 18.75% | 10.8108% | 19.3878% | 9.2593% | -36.1446% | -18.5714% | -4.4776% | 25.6098% | 25% | 56.9444% | 42.6966% | -1.1628% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.94 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MLYS
2026-02-19 20:27:04
Options trading for Mineralys Therapeutics Inc (MLYS) indicates an anticipated 21.7% movement in its share price following its upcoming earnings release. The normal volume of pre-earnings options shows puts significantly outnumbering calls (56:1). This implied volatility suggests a much larger move than the company's historical median of 4.2% over the last eight quarters.
2026-02-19 08:28:32
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) has received an average recommendation of "Moderate Buy" from eight ratings firms, with an average twelve-month price objective of $47.4286. Recent analyst reports have seen price targets boosted, though one firm reiterated a "sell" rating. Insider sales activity by a company executive and CFO decreased their respective stock holdings, while institutional investors and hedge funds have recently increased their positions in the company.
2026-02-18 14:27:23
David Malcom Rodman, an insider at Mineralys Therapeutics (NASDAQ:MLYS), recently sold 417 shares of the company's stock for $27.59 per share, totaling $11,505.03. This sale decreased his position by 0.94%, leaving him with 44,089 shares valued at approximately $1.22 million. The company's stock traded higher at $27.94 with an average analyst rating of "Moderate Buy" and a target price of $47.43, despite trading below its 50- and 200-day moving averages.
2026-02-18 01:58:41
Chief Medical Officer David Malcom Rodman of Mineralys Therapeutics (MLYS) sold 417 shares of company stock for $11,505 on February 17, 2026, after exercising options for the same number of shares. This transaction occurred via a Rule 10b5-1 trading plan and follows a significant 191% surge in the stock over the past year. Analysts rate Mineralys as a Strong Buy, with the company set to report earnings on March 18.
2026-02-18 00:57:31
Mineralys Therapeutics Chief Medical Officer, David Malcom Rodman, sold 417 shares of common stock for $11,505 on February 17, 2026, after exercising options for the same number of shares. This transaction occurred after the company's stock surged 191% over the past year, and analysts rate it a "Strong Buy" with price targets between $42 and $56. The company is also making significant progress with its lead asset, lorundrostat, for hypertension treatment, with an NDA preparation underway and recognition of its Phase 3 trial in JAMA.
2026-02-15 03:57:38
Mineralys Therapeutics Inc. (NASDAQ: MLYS) is showing weak near and mid-term sentiment, despite a positive long-term outlook, with a breakdown currently underway suggesting lower levels are expected. The article presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, alongside multi-timeframe signal analysis indicating varying support and resistance levels. These strategies provide specific entry, target, and stop-loss zones for tactical trading decisions.
